Serum Markers of Bone Turnover and Angiogenesis in Patients with Bisphosphonate-Related Osteonecrosis of the Jaw after Discontinuation of Long-Term Intravenous Bisphosphonate Therapy

Vivek Thumbigere-Math, Bryan S. Michalowicz, Pamela Hughes, David L. Basi, Michaela L. Tsai, Karen K. Swenson, Laura Rockwell, Rajaram Gopalakrishnan

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose To analyze serum markers of bone turnover, angiogenesis, endocrine function, and inflammation in patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ) who discontinued long-term intravenous bisphosphonate (BP) therapy. Patients and Methods Serum samples were obtained from 25 BRONJ patients who had discontinued long-term intravenous BP therapy for an average of 11.4 ± 8.7 months and 48 non-BRONJ controls who continued receiving intravenous BP therapy. Samples were analyzed for total alkaline phosphatase, bone-specific alkaline phosphatase, osteocalcin, C-telopeptide, vascular endothelial growth factor, triiodothyronine, thyroxine, thyroid-stimulating hormone, 25-hydroxyvitamin D, and C-reactive protein. Results The mean number of BP infusions was significantly higher in BRONJ patients compared with controls (38.4 ± 26.3 infusions vs 18.8 ± 7.2 infusions, P 10 vascular endothelial growth factor (2.9 ± 0.4 pg/mL vs 2.4 ± 0.4 pg/mL, P

Original languageEnglish (US)
Pages (from-to)738-746
Number of pages9
JournalJournal of Oral and Maxillofacial Surgery
Volume74
Issue number4
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

Fingerprint

Bisphosphonate-Associated Osteonecrosis of the Jaw
Bone Remodeling
Diphosphonates
Biomarkers
Vascular Endothelial Growth Factor A
Alkaline Phosphatase
Dilatation and Curettage
Osteonecrosis
Osteocalcin
Triiodothyronine
Thyrotropin
Therapeutics
Jaw
Thyroxine
Inflammation
Bone and Bones
Serum
Proteins

ASJC Scopus subject areas

  • Oral Surgery
  • Otorhinolaryngology
  • Surgery

Cite this

Serum Markers of Bone Turnover and Angiogenesis in Patients with Bisphosphonate-Related Osteonecrosis of the Jaw after Discontinuation of Long-Term Intravenous Bisphosphonate Therapy. / Thumbigere-Math, Vivek; Michalowicz, Bryan S.; Hughes, Pamela; Basi, David L.; Tsai, Michaela L.; Swenson, Karen K.; Rockwell, Laura; Gopalakrishnan, Rajaram.

In: Journal of Oral and Maxillofacial Surgery, Vol. 74, No. 4, 01.04.2016, p. 738-746.

Research output: Contribution to journalArticle

Thumbigere-Math, Vivek ; Michalowicz, Bryan S. ; Hughes, Pamela ; Basi, David L. ; Tsai, Michaela L. ; Swenson, Karen K. ; Rockwell, Laura ; Gopalakrishnan, Rajaram. / Serum Markers of Bone Turnover and Angiogenesis in Patients with Bisphosphonate-Related Osteonecrosis of the Jaw after Discontinuation of Long-Term Intravenous Bisphosphonate Therapy. In: Journal of Oral and Maxillofacial Surgery. 2016 ; Vol. 74, No. 4. pp. 738-746.
@article{706e98856dac48189e6f68239259c6e3,
title = "Serum Markers of Bone Turnover and Angiogenesis in Patients with Bisphosphonate-Related Osteonecrosis of the Jaw after Discontinuation of Long-Term Intravenous Bisphosphonate Therapy",
abstract = "Purpose To analyze serum markers of bone turnover, angiogenesis, endocrine function, and inflammation in patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ) who discontinued long-term intravenous bisphosphonate (BP) therapy. Patients and Methods Serum samples were obtained from 25 BRONJ patients who had discontinued long-term intravenous BP therapy for an average of 11.4 ± 8.7 months and 48 non-BRONJ controls who continued receiving intravenous BP therapy. Samples were analyzed for total alkaline phosphatase, bone-specific alkaline phosphatase, osteocalcin, C-telopeptide, vascular endothelial growth factor, triiodothyronine, thyroxine, thyroid-stimulating hormone, 25-hydroxyvitamin D, and C-reactive protein. Results The mean number of BP infusions was significantly higher in BRONJ patients compared with controls (38.4 ± 26.3 infusions vs 18.8 ± 7.2 infusions, P 10 vascular endothelial growth factor (2.9 ± 0.4 pg/mL vs 2.4 ± 0.4 pg/mL, P",
author = "Vivek Thumbigere-Math and Michalowicz, {Bryan S.} and Pamela Hughes and Basi, {David L.} and Tsai, {Michaela L.} and Swenson, {Karen K.} and Laura Rockwell and Rajaram Gopalakrishnan",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.joms.2015.09.028",
language = "English (US)",
volume = "74",
pages = "738--746",
journal = "Journal of Oral and Maxillofacial Surgery",
issn = "0278-2391",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Serum Markers of Bone Turnover and Angiogenesis in Patients with Bisphosphonate-Related Osteonecrosis of the Jaw after Discontinuation of Long-Term Intravenous Bisphosphonate Therapy

AU - Thumbigere-Math, Vivek

AU - Michalowicz, Bryan S.

AU - Hughes, Pamela

AU - Basi, David L.

AU - Tsai, Michaela L.

AU - Swenson, Karen K.

AU - Rockwell, Laura

AU - Gopalakrishnan, Rajaram

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Purpose To analyze serum markers of bone turnover, angiogenesis, endocrine function, and inflammation in patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ) who discontinued long-term intravenous bisphosphonate (BP) therapy. Patients and Methods Serum samples were obtained from 25 BRONJ patients who had discontinued long-term intravenous BP therapy for an average of 11.4 ± 8.7 months and 48 non-BRONJ controls who continued receiving intravenous BP therapy. Samples were analyzed for total alkaline phosphatase, bone-specific alkaline phosphatase, osteocalcin, C-telopeptide, vascular endothelial growth factor, triiodothyronine, thyroxine, thyroid-stimulating hormone, 25-hydroxyvitamin D, and C-reactive protein. Results The mean number of BP infusions was significantly higher in BRONJ patients compared with controls (38.4 ± 26.3 infusions vs 18.8 ± 7.2 infusions, P 10 vascular endothelial growth factor (2.9 ± 0.4 pg/mL vs 2.4 ± 0.4 pg/mL, P

AB - Purpose To analyze serum markers of bone turnover, angiogenesis, endocrine function, and inflammation in patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ) who discontinued long-term intravenous bisphosphonate (BP) therapy. Patients and Methods Serum samples were obtained from 25 BRONJ patients who had discontinued long-term intravenous BP therapy for an average of 11.4 ± 8.7 months and 48 non-BRONJ controls who continued receiving intravenous BP therapy. Samples were analyzed for total alkaline phosphatase, bone-specific alkaline phosphatase, osteocalcin, C-telopeptide, vascular endothelial growth factor, triiodothyronine, thyroxine, thyroid-stimulating hormone, 25-hydroxyvitamin D, and C-reactive protein. Results The mean number of BP infusions was significantly higher in BRONJ patients compared with controls (38.4 ± 26.3 infusions vs 18.8 ± 7.2 infusions, P 10 vascular endothelial growth factor (2.9 ± 0.4 pg/mL vs 2.4 ± 0.4 pg/mL, P

UR - http://www.scopus.com/inward/record.url?scp=84961910374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961910374&partnerID=8YFLogxK

U2 - 10.1016/j.joms.2015.09.028

DO - 10.1016/j.joms.2015.09.028

M3 - Article

C2 - 26501428

AN - SCOPUS:84961910374

VL - 74

SP - 738

EP - 746

JO - Journal of Oral and Maxillofacial Surgery

JF - Journal of Oral and Maxillofacial Surgery

SN - 0278-2391

IS - 4

ER -